CBLL vs LNTH vs HTFL Stock Comparison

Ceribell, Lantheus Holdings and Heartflow Prices as of Nov 16, 2026 Peers: Industry group
CBLL Ceribell, Inc.
$26.42 +5.5% 1M +104.8% 1Y
Market cap
$999.85M
P/E
–
Revenue (TTM)
$108.72M
Div. yield
–
Diagnostic Equipment Healthcare
1 win
LNTH Lantheus Holdings, Inc.
$101.72 +2.0% 1M +91.9% 1Y
Market cap
$6.65B
P/E
24.6x
Revenue (TTM)
$1.56B
Div. yield
–
Diagnostic Equipment Healthcare
6 wins
HTFL Heartflow, Inc.
$46.86 -3.0% 1M +67.5% 1Y
Market cap
$4.09B
P/E
–
Revenue (TTM)
$238.66M
Div. yield
–
Diagnostic Equipment Healthcare
1 win

Head to Head

8 decided of 12

Lantheus Holdings leads on 6 of the 12 questions below (Lantheus Holdings 6, Heartflow 1, Ceribell 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionCBLLLNTHHTFLLeader
Larger companyMarket capitalisation $999.85M $6.65B $4.09B LNTH
Cheaper on earningsLower P/E, profitable companies only -13.5x 24.6x -51.8x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 17.4x — –
Faster revenue growthRevenue growth, trailing twelve months +31.3% +2.4% +47.4% HTFL
More profitableNet margin, trailing twelve months -68.0% 17.3% -33.1% LNTH
Better return on capitalReturn on invested capital — 12.0% -27.5% LNTH
Less leveragedLower net debt / EBITDA 1.3x -0.3x 3.4x LNTH
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +104.8% +91.9% +67.5% CBLL
Better 5-year returnAnnualised price return, 5 years — +28.3%/yr — –
Less volatileAnnualised volatility, 1 year 51.5% 30.1% 78.3% LNTH
Higher overall scoreMean of the five percentile scores vs peers 39/100 80/100 57/100 LNTH

Percentile Scorecard

CBLLLNTHHTFL

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisCBLLLNTHHTFL
Valuation 23 #188 of 243 80 #49 of 243 30 #170 of 243
Growth 21 #180 of 228 70 #69 of 228 79 #49 of 228
Profitability 36 #142 of 222 96 #11 of 222 52 #107 of 222
Financial Health 79 #52 of 248 69 #77 of 248 82 #45 of 248
Shareholder Returns 37 #101 of 159 85 #24 of 159 42 #92 of 159
Overall 39 80 57
  • CBLL ranked among 252 companies in Medical Devices and Diagnostics
  • LNTH ranked among 252 companies in Medical Devices and Diagnostics
  • HTFL ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodCBLLLNTHHTFLSPY
1 month +5.5%+2.0%-3.0% -3.0%
3 months +8.3%+0.8%+11.7% -4.2%
6 months +59.3%+9.2%+82.7% +0.2%
Year to date +20.5%+52.8%+60.8% +8.5%
1 year +104.8%+91.9%+67.5% +10.1%
3 years —+49.1%— +64.1%
3 years, per year —+14.3%— +18.0%
5 years —+247.3%— +58.1%
5 years, per year —+28.3%— +9.6%
10 years —+1,024.0%— +239.6%
10 years, per year —+27.4%— +13.0%

Risk

MeasureCBLLLNTHHTFLSPY
Volatility, 1Y 51.5%30.1%78.3% 13.8%
Downside volatility, 1Y 50.0%24.7%80.6% 14.2%
Beta vs S&P 500, 1Y 1.130.451.91 1.00
Return / volatility, 1Y 2.043.050.86 0.74
Max drawdown, 5Y -63.9%-59.5%-48.7% -25.4%
From 52-week high -6.5%-8.3%-22.6% -5.0%
52-week high $28.27$110.94$60.53 $779.14
52-week low $12.89$52.50$20.49 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleCBLLLNTHHTFL
P/E now vs peer median -13.6xmedian 26.5x 24.6xmedian 26.5x -53.5xmedian 26.5x
P/S now vs peer median 9.3xmedian 2.7x 4.3xmedian 2.7x 17.8xmedian 2.7x
EV/EBITDA now vs peer median -12.3xmedian 18.6x 16.9xmedian 18.6x -54.4xmedian 18.6x
P/FCF now vs peer median -18.0xmedian 25.6x 16.9xmedian 25.6x -75.9xmedian 25.6x
P/B now vs peer median 8.6xmedian 2.5x 4.9xmedian 2.5x 15.1xmedian 2.5x
PEG now vs peer median —median 0.98 0.64median 0.98 —median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsCBLLLNTHHTFL
Revenue $108.72M $1.56B $238.66M
Gross profit $97.04M $957.06M $195.33M
Operating income -$75.87M $290.93M -$79.00M
Net income -$73.88M $269.91M -$79.02M
Free cash flow -$56.43M $393.09M -$56.07M
R&D $25.37M $217.83M $96.03M
EPS (diluted) $-1.92 $3.95 $-0.91
Cash & equivalents $41.99M $683.61M $31.65M
Total debt $21.22M $571.74M $2.93M
Shares (diluted) 38.50M 68.41M 87.25M
Enterprise value $452.67M $4.51B $3.84B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricCBLLLNTHHTFL
P/E -13.6x 24.6x -53.5x
P/FCF -18.0x 16.9x -75.9x
P/Operating cash flow -18.1x 16.2x -86.9x
P/S 9.3x 4.3x 17.8x
P/B 8.6x 4.9x 15.1x
P/Tangible book 8.6x 9.3x 15.1x
EV/EBITDA -12.3x 16.9x -54.4x
EV/EBIT -12.1x 22.5x -50.7x
EV/Revenue 8.4x 4.2x 16.8x
EV/FCF -16.3x 16.6x -71.4x
EV/Operating cash flow -16.4x 16.0x -81.8x
PEG (3Y EPS CAGR) – 0.64 –

Growth

14 metrics
MetricCBLLLNTHHTFL
Revenue growth (1Y) 31.3% 2.4% 47.4%
Revenue CAGR (3Y) – 9.0% –
Gross profit growth (1Y) 33.2% 0.8% 59.6%
Gross profit CAGR (3Y) – 13.9% –
Operating income growth (1Y) -33.8% -16.3% -26.7%
Operating income CAGR (3Y) – 73.7% –
Net income growth (1Y) -40.8% 61.0% 37.0%
Net income CAGR (3Y) – 37.4% –
EPS growth (1Y) -34.6% 59.2% 64.5%
EPS CAGR (3Y) – 38.5% –
Operating cash flow growth (1Y) -40.0% -10.5% 14.8%
Operating cash flow CAGR (3Y) – 11.1% –
Free cash flow growth (1Y) -37.8% -5.1% 8.0%
Free cash flow CAGR (3Y) – 119.0% –

Profitability

14 metrics
MetricCBLLLNTHHTFL
Gross margin 89.3% 61.3% 81.8%
EBITDA margin -68.4% 24.7% -30.8%
Operating margin -69.8% 18.6% -33.1%
Pretax margin -68.0% 21.9% -33.2%
Net margin -68.0% 17.3% -33.1%
FCF margin -51.9% 25.2% -23.5%
Operating cash flow margin -51.5% 26.2% -20.5%
Return on equity -60.3% 20.2% 13.0%
Return on assets -46.0% 11.1% 10.5%
Return on invested capital – 12.0% -27.5%
Return on capital employed -52.9% 13.9% -26.6%
Asset turnover 0.7x 0.6x 0.7x
Cash conversion (OCF / net income) 0.8x 1.5x 0.6x
Stock comp / revenue 18.6% 4.8% 11.4%

Financial Health

11 metrics
MetricCBLLLNTHHTFL
Debt / assets 13.6% 23.3% 0.8%
Debt / equity 0.2x 0.4x 0.0x
Net debt / EBITDA 1.3x -0.3x 3.4x
Debt / FCF -0.4x 1.5x -0.1x
Liabilities / assets 24.8% 44.8% 20.5%
Equity / assets 75.2% 55.2% 79.5%
Interest coverage -47.4x 14.7x -4,938x
Current ratio 8.2x 3.2x 4.4x
Quick ratio 7.6x 3.0x 5.7x
Cash ratio 6.5x 2.0x 4.7x
Altman Z-score 13.25 5.54 31.11

Shareholder Returns

7 metrics
MetricCBLLLNTHHTFL
Dividend yield – – –
Net buyback yield -0.8% 1.3% -0.4%
Shareholder yield -0.8% 1.3% -0.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusCBLLLNTHHTFL
Forward P/E – 17.4xFY2026 –
EPS, next fiscal year $-1.96FY2026 $5.83FY2026 $-0.43FY2026
EPS growth, next FY – -4.1%FY2026 –
EPS growth, the year after – +7.2% –
Revenue, next fiscal year $118.62MFY2026 $1.58BFY2026 $263.06MFY2026
Revenue growth, next FY +33.2%FY2026 +2.5%FY2026 +49.4%FY2026
Revenue growth, the year after +21.3% +12.6% +20.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersCBLLLNTHHTFL
Held by institutions 79.9% 100.0% 100.0%
Institutions holding 124 468 193
Change in shares held, QoQ +2.2% +3.4% +133.0%
Institutions buying 74 249 140
Institutions selling 36 143 38
Buyers to sellers 2.06 1.74 3.68

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

CBLLLNTHHTFL
CBLL 1.00 0.20 0.26
LNTH 0.20 1.00 0.09
HTFL 0.26 0.09 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, CBLL, LNTH and HTFL?

Lantheus Holdings (LNTH) is the largest by market capitalisation: Ceribell (CBLL) $999.85M, Lantheus Holdings (LNTH) $6.65B, Heartflow (HTFL) $4.09B.

Which company is growing faster?

Heartflow (HTFL) grew revenue fastest over the trailing twelve months: Ceribell (CBLL) +31.3%, Lantheus Holdings (LNTH) +2.4%, Heartflow (HTFL) +47.4%.

Which company is more profitable?

Lantheus Holdings (LNTH) has the highest net margin (Ceribell (CBLL) -68.0%, Lantheus Holdings (LNTH) 17.3%, Heartflow (HTFL) -33.1%). On return on invested capital, Lantheus Holdings (LNTH) leads (Lantheus Holdings (LNTH) 12.0%, Heartflow (HTFL) -27.5%).

Which stock has performed better?

Over the past year Ceribell (CBLL) returned the most: Ceribell (CBLL) +104.8%, Lantheus Holdings (LNTH) +91.9%, Heartflow (HTFL) +67.5%. Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Lantheus Holdings (LNTH) has been the steadiest (Ceribell (CBLL) 51.5%, Lantheus Holdings (LNTH) 30.1%, Heartflow (HTFL) 78.3%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, CBLL, LNTH and HTFL?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Lantheus Holdings (LNTH) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.